Stay updated on Pembrolizumab vs Placebo in Stage II Melanoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs Placebo in Stage II Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs Placebo in Stage II Melanoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T23:21:21.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details related to the safety and efficacy of pembrolizumab compared to placebo in participants with surgically resected high-risk Stage II melanoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:47:13.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying that researchers are looking for individuals with a new diagnosis of Stage IIB or IIC cutaneous melanoma, among other health conditions and prior treatments. Previously, this section had no information provided.
    Difference
    16%
    Check dated 2024-05-22T21:20:53.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.5%
    Check dated 2024-04-30T22:25:12.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs Placebo in Stage II Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Placebo in Stage II Melanoma Clinical Trial page.